Research status and advances in immunotherapy for chronic myeloid leukemia
10.13303/j.cjbt.issn.1004-549x.2025.05.022
- VernacularTitle:慢性粒细胞白血病免疫治疗研究现状及进展
- Author:
Mengmeng WANG
1
;
Jingyun MA
1
;
Boyu XIONG
1
;
Zhuowen DAI
1
;
Yueyue PAN
1
;
Qiong WANG
2
Author Information
1. Laboratory Department, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi Medical Center of Nanjing Medical University, Wuxi 214000, China
2. Blood Transfusion Department, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi Medical Center of Nanjing Medical University, Wuxi 214000, China
- Publication Type:Journal Article
- Keywords:
chronic myeloid leukemia;
immunotherapy;
T cells;
NK cells;
telomeres
- From:
Chinese Journal of Blood Transfusion
2025;38(5):739-746
- CountryChina
- Language:Chinese
-
Abstract:
Chronic myeloid leukemia (CML) is a malignant hematologic disorder caused by abnormal proliferation of hematopoietic stem cells. In recent years, while the application of tyrosine kinase inhibitors (TKIs) has significantly improved the prognosis of CML patients through in-depth exploration of pathogenesis of CML and advancements in targeted therapies, some patients still face challenges including drug resistance, disease relapse, and failure to achieve treatment-free remission. Imunotherapy, as a complementary or alternative strategy, holds significant potential for overcoming these limitations, and has gradually emerged as a critical research focus in CML treatment. This review aims to summarize the current research status and latest advances in immunotherapy for CML.
